Tag: Serranator

Sectoral Asset Management makes US$9 million investment into Cagent Vascular

Cagent Vascular recently announced the investment of US$9 million by Sectoral Asset Management. Along with the investment, Marc-Andre Marcotte has joined the board of...

LINC 2021: PRELUDE-BTK results confirm Serranator device novel mechanism of action

Cagent Vascular announced the results of its PRELUDE-BTK study at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online). The PRELUDE-BTK study was a...

Cagent Vascular appoints Brian Walsh as chairman of the board

Cagent Vascular, a developer of next-generation angioplasty balloons using proprietary serration technology, announces Brian Walsh to serve as chairman of the Board. Brian Walsh...
Serranator Alto

Serranator PTA serration balloon catheter receives CE mark

Cagent Vascular has announced the issuance of its CE marking for the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter. Cagent Vascular has also achieved...

Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device

Cagent Vascular has announced the completion of enrolment in the first-in-human PRELUDE study. The purpose of this prospective, single-arm, multicentre feasibility study is to...

Cagent Vascular announces FDA 510(k) clearance of Serranator Alto serration balloon...

Cagent Vascular has announced US Food and Drug Administration 510(k) clearance of its lead product, the Serranator Alto percutaneous transluminal angioplasty serration balloon catheter. The Serranator...